MBX Biosciences, Inc. Stock-Based Compensation
MBX Biosciences, Inc. (MBX) reported Stock-Based Compensation of $11.55 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- MBX Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $6.06M, a 213.06% increase year-over-year.
- MBX Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $5.48M, a 198.21% increase year-over-year.
- MBX Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.66M, a 78.49% increase year-over-year.
- MBX Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.25M, a 88.34% increase year-over-year.
- MBX Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $8.68M, a 66.16% increase from fiscal 2024.
- MBX Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $5.22M, a 155.60% increase from fiscal 2023.
- MBX Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $2.04M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.55M 10-Q · filed 2026-08-06 | $14.20M derived: sum of 3 quarters · filed 2026-08-06 | $16.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.48M 10-Q · filed 2026-05-07 | $8.14M derived: sum of 2 quarters · filed 2026-05-07 | $10.38M derived: sum of 3 quarters · filed 2026-05-07 | $12.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.90M derived: sum of 2 quarters · filed 2026-03-12 | $6.84M derived: sum of 3 quarters · filed 2026-08-06 | $8.68M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.18M derived: sum of 2 quarters · filed 2026-08-06 | $6.02M 10-Q · filed 2025-11-06 | $7.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.78M 10-Q · filed 2026-08-06 | $5.26M derived: sum of 3 quarters · filed 2026-08-06 | $6.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.84M 10-Q · filed 2026-05-07 | $3.33M derived: sum of 2 quarters · filed 2026-05-07 | $4.52M derived: sum of 3 quarters · filed 2026-05-07 | $5.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.68M derived: sum of 2 quarters · filed 2026-03-12 | $3.60M derived: sum of 3 quarters · filed 2026-03-12 | $5.22M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.11M derived: sum of 2 quarters · filed 2025-11-06 | $3.73M 10-Q · filed 2025-11-06 | $4.75M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $919.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.54M 10-Q · filed 2025-08-07 | $3.56M derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | $1.62M 10-Q · filed 2025-05-12 | $2.64M derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $2.04M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $1.02M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |